{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:16:52Z","timestamp":1794647812523,"version":"4.9.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","award":["2025-2026-2024-2028"],"award-info":[{"award-number":["2025-2026-2024-2028"]}],"id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["SG-231061717"],"award-info":[{"award-number":["SG-231061717"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ZEN 24-I 069572"],"award-info":[{"award-number":["ZEN 24-I 069572"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Aging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The\n                    <jats:italic>APOE<\/jats:italic>\n                    locus is the strongest genetic factor for Alzheimer\u2019s disease, with \u03b54 increasing and \u03b52 decreasing risk, yet the basis of these opposing effects remains unclear. Here we performed a multicohort proteomic analysis across plasma and cerebrospinal fluid in GNPC, BioFINDER-2, ADNI, UK BioBank, and PPMI.\n                    <jats:italic>APOE<\/jats:italic>\n                    -associated protein alterations are detectable before amyloid pathology and remain stable across age and disease progression.\n                    <jats:italic>APOE2<\/jats:italic>\n                    -associated proteins were enriched in pathways related to cellular maintenance and anti-inflammatory processes. By contrast,\n                    <jats:italic>APOE4<\/jats:italic>\n                    showed a limited set of upstream mediators linked to cell-cycle and oligodendrocyte precursor cell biology, and a broader group of proteins reflecting vascular, immune, and proteostatic dysfunction shaped by downstream pathology. Comparative analyses highlighted allele-specific mediators and oppositely regulated proteins contributing to differential disease risk. Together, these findings reveal that\n                    <jats:italic>APOE2<\/jats:italic>\n                    and\n                    <jats:italic>APOE4<\/jats:italic>\n                    shape Alzheimer\u2019s disease risk through distinct molecular architectures and identify candidate biomarkers and targets for allele-specific interventions.\n                  <\/jats:p>","DOI":"10.1038\/s43587-026-01123-0","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:02:46Z","timestamp":1778835766000},"page":"1138-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Proteomic signatures of the APOE \u03b54 and APOE \u03b52 genetic variants and Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-242X","authenticated-orcid":false,"given":"Lina","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Pichet Binette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Hristovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-8378","authenticated-orcid":false,"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Smets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cumplido-Mayoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Vasanthakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britney","family":"Milkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Global Neurodegeneration Proteomics Consortium (GNPC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-4625","authenticated-orcid":false,"given":"Lijun","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Krish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-2568","authenticated-orcid":false,"given":"Farhad","family":"Imam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-9940","authenticated-orcid":false,"given":"Jacob W.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"1123_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261, 921\u2013923 (1993).","journal-title":"Science"},{"key":"1123_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","volume":"16","author":"E Genin","year":"2011","unstructured":"Genin, E. et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 16, 903\u2013907 (2011).","journal-title":"Mol. Psychiatry"},{"key":"1123_CR3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"C-C Liu","year":"2017","unstructured":"Liu, C.-C. et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron 96, 1024\u20131032.e3 (2017).","journal-title":"Neuron"},{"key":"1123_CR4","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman, D. M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 97, 2892\u20132897 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1123_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","volume":"14","author":"N Mattsson","year":"2018","unstructured":"Mattsson, N. et al. Prevalence of the apolipoprotein E \u03b54 allele in amyloid \u03b2 positive subjects across the spectrum of Alzheimer\u2019s disease. Alzheimers Dement. 14, 913\u2013924 (2018).","journal-title":"Alzheimers Dement."},{"key":"1123_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14279-8","volume":"11","author":"EM Reiman","year":"2020","unstructured":"Reiman, E. M. et al. Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat. Commun. 11, 667 (2020).","journal-title":"Nat. Commun."},{"key":"1123_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo, A., Das, S. & Hyman, B. T. APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 20, 68\u201380 (2021).","journal-title":"Lancet Neurol."},{"key":"1123_CR8","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0896-6273(93)90070-8","volume":"11","author":"GW Rebeck","year":"1993","unstructured":"Rebeck, G. W., Reiter, J. S., Strickland, D. K. & Hyman, B. T. Apolipoprotein E in sporadic Alzheimer\u2019s disease: allelic variation and receptor interactions. Neuron 11, 575\u2013580 (1993).","journal-title":"Neuron"},{"key":"1123_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18198-x","volume":"11","author":"TE Goldberg","year":"2020","unstructured":"Goldberg, T. E., Huey, E. D. & Devanand, D. P. Association of APOE e2 genotype with Alzheimer\u2019s and non-Alzheimer\u2019s neurodegenerative pathologies. Nat. Commun. 11, 4727 (2020).","journal-title":"Nat. Commun."},{"key":"1123_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamaneurol.2020.3780","volume":"78","author":"PS Insel","year":"2021","unstructured":"Insel, P. S., Hansson, O. & Mattsson-Carlgren, N. Association between apolipoprotein E \u03b52 vs \u03b54, age, and \u03b2-amyloid in adults without cognitive impairment. JAMA Neurol. 78, 229\u2013235 (2021).","journal-title":"JAMA Neurol."},{"key":"1123_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf016","author":"C Cicognola","year":"2025","unstructured":"Cicognola, C. et al. APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta. Brain https:\/\/doi.org\/10.1093\/brain\/awaf016 (2025).","journal-title":"Brain"},{"key":"1123_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2015.177","volume":"21","author":"JI V\u00e9lez","year":"2016","unstructured":"V\u00e9lez, J. I. et al. APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer\u2019s disease. Mol. Psychiatry 21, 916\u2013924 (2016).","journal-title":"Mol. Psychiatry"},{"key":"1123_CR13","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1038\/s41591-025-03835-z","volume":"31","author":"A Shvetcov","year":"2025","unstructured":"Shvetcov, A. et al. APOE \u03b54 carriers share immune-related proteomic changes across neurodegenerative diseases. Nat. Med. 31, 2590\u20132601 (2025).","journal-title":"Nat. Med."},{"key":"1123_CR14","first-page":"11","volume":"1","author":"F Imam","year":"2025","unstructured":"Imam, F. et al. The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging. Nat. Med. 1, 11 (2025).","journal-title":"Nat. Med."},{"key":"1123_CR15","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s43587-024-00693-1","volume":"4","author":"EA Frick","year":"2024","unstructured":"Frick, E. A. et al. Serum proteomics reveal APOE-\u03b54-dependent and APOE-\u03b54-independent protein signatures in Alzheimer\u2019s disease. Nat. Aging 4, 1446\u20131464 (2024).","journal-title":"Nat. Aging"},{"key":"1123_CR16","first-page":"21","volume":"1","author":"S Afshar","year":"2025","unstructured":"Afshar, S. et al. Plasma proteomic associations with Alzheimer\u2019s disease endophenotypes. Nat. Aging 1, 21 (2025).","journal-title":"Nat. Aging"},{"key":"1123_CR17","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.3390\/ijms26157303","volume":"26","author":"S D\u2019Angiolini","year":"2025","unstructured":"D\u2019Angiolini, S., Gugliandolo, A., Cal\u00ec, G. & Chiricosta, L. Early dysregulation of RNA splicing and translation processes are key markers from mild cognitive impairment to Alzheimer\u2019s disease: an in silico transcriptomic analysis. Int. J. Mol. Sci. 26, 7303 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1123_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat. Genet. 45, 1452\u20131458 (2013).","journal-title":"Nat. Genet."},{"key":"1123_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-022-02454-z","volume":"144","author":"IE Jansen","year":"2022","unstructured":"Jansen, I. E. et al. Genome-wide meta-analysis for Alzheimer\u2019s disease cerebrospinal fluid biomarkers. Acta Neuropathol. 144, 821\u2013842 (2022).","journal-title":"Acta Neuropathol."},{"key":"1123_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.14336\/AD.2020.0105","volume":"11","author":"W Li","year":"2020","unstructured":"Li, W., Kui, L., Demetrios, T., Gong, X. & Tang, M. A glimmer of hope: maintain mitochondrial homeostasis to mitigate Alzheimer\u2019s disease. Aging Dis. 11, 1260\u20131275 (2020).","journal-title":"Aging Dis."},{"key":"1123_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00415-024-12800-8","volume":"272","author":"Y Yuan","year":"2024","unstructured":"Yuan, Y., Zhao, G. & Zhao, Y. Dysregulation of energy metabolism in Alzheimer\u2019s disease. J. Neurol. 272, 2 (2024).","journal-title":"J. Neurol."},{"key":"1123_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2011.12.057","volume":"51","author":"JE Selfridge","year":"2013","unstructured":"Selfridge, J. E., E, L., Lu, J. & Swerdlow, R. H. Role of mitochondrial homeostasis and dynamics in Alzheimer\u2019s disease. Neurobiol. Dis. 51, 3\u201312 (2013).","journal-title":"Neurobiol. Dis."},{"key":"1123_CR23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2147\/CCID.S506139","volume":"18","author":"R Tao","year":"2025","unstructured":"Tao, R. et al. Mendelian randomization combined with single-cell transcriptome analysis reveals the role of the key gene PCLAF in the pathogenesis of atopic dermatitis. Clin. Cosmet. Investig. Dermatol. 18, 867\u2013882 (2025).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"1123_CR24","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.21037\/atm-21-4064","volume":"9","author":"F Cui","year":"2021","unstructured":"Cui, F., Xu, Z., Lv, Y. & Hu, J. Role of spindle pole body component 25 in neurodegeneration. Ann. Transl. Med. 9, 1432 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1123_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17293-2","volume":"7","author":"S-M Shim","year":"2017","unstructured":"Shim, S.-M., Kim, J.-H. & Jeon, J.-P. Effective litmus gene test for monitoring the quality of blood samples: application to Alzheimer\u2019s disease diagnostics. Sci. Rep. 7, 16848 (2017).","journal-title":"Sci. Rep."},{"key":"1123_CR26","doi-asserted-by":"publisher","first-page":"e60718","DOI":"10.1371\/journal.pone.0060718","volume":"8","author":"A Granic","year":"2013","unstructured":"Granic, A. & Potter, H. Mitotic spindle defects and chromosome mis-segregation induced by LDL\/cholesterol-implications for Niemann-Pick C1, Alzheimer\u2019s disease, and atherosclerosis. PLoS ONE 8, e60718 (2013).","journal-title":"PLoS ONE"},{"key":"1123_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/978-3-642-19065-0_23","volume":"53","author":"C Moh","year":"2011","unstructured":"Moh, C. et al. Cell cycle deregulation in the neurons of Alzheimer\u2019s disease. Results Probl. Cell Differ. 53, 565\u2013576 (2011).","journal-title":"Results Probl. Cell Differ."},{"key":"1123_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1750-1326-6-80","volume":"6","author":"M Judge","year":"2011","unstructured":"Judge, M., Hornbeck, L., Potter, H. & Padmanabhan, J. Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Mol. Neurodegener. 6, 80 (2011).","journal-title":"Mol. Neurodegener."},{"key":"1123_CR29","doi-asserted-by":"publisher","first-page":"946","DOI":"10.14336\/AD.2019.0923","volume":"11","author":"C Joseph","year":"2020","unstructured":"Joseph, C. et al. Cell cycle deficits in neurodegenerative disorders: uncovering molecular mechanisms to drive innovative therapeutic development. Aging Dis. 11, 946\u2013966 (2020).","journal-title":"Aging Dis."},{"key":"1123_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/sj.cdd.4400764","volume":"7","author":"CT McMurray","year":"2000","unstructured":"McMurray, C. T. Neurodegeneration: diseases of the cytoskeleton?. Cell Death Differ. 7, 861\u2013865 (2000).","journal-title":"Cell Death Differ."},{"key":"1123_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/br.2022.1510","volume":"16","author":"JA Guti\u00e9rrez-Vargas","year":"2022","unstructured":"Guti\u00e9rrez-Vargas, J. A., Castro-\u00c1lvarez, J. F., Zapata-Berruecos, J. F., Abdul-Rahim, K. & Arteaga-Noriega, A. Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer\u2019s disease, cerebral ischemia and multiple sclerosis (Review). Biomed. Rep. 16, 27 (2022).","journal-title":"Biomed. Rep."},{"key":"1123_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/acel.14439","volume":"24","author":"A Shvetcov","year":"2025","unstructured":"Shvetcov, A. et al. Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype. Aging Cell 24, e14439 (2025).","journal-title":"Aging Cell"},{"key":"1123_CR33","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s43587-025-00872-8","volume":"5","author":"G Heo","year":"2025","unstructured":"Heo, G. et al. Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer\u2019s disease. Nat. Aging 5, 1114\u20131131 (2025).","journal-title":"Nat. Aging"},{"key":"1123_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WAD.0b013e318299d096","volume":"28","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. The effect of APOE \u03b54 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging. Alzheimer Dis. Assoc. Disord. 28, 122\u2013127 (2014).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"1123_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.kjms.2017.04.006","volume":"33","author":"T-H Chen","year":"2017","unstructured":"Chen, T.-H. et al. Factors affecting therapeutic response to rivastigmine in Alzheimer\u2019s disease patients in Taiwan. Kaohsiung J. Med. Sci. 33, 277\u2013283 (2017).","journal-title":"Kaohsiung J. Med. Sci."},{"key":"1123_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1139\/jpn.0302","volume":"28","author":"KL Lanct\u00f4t","year":"2003","unstructured":"Lanct\u00f4t, K. L., Herrmann, N. & LouLou, M. M. Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer\u2019s disease. J. Psychiatry Neurosci. 28, 13\u201326 (2003).","journal-title":"J. Psychiatry Neurosci."},{"key":"1123_CR37","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1002\/alz.13821","volume":"20","author":"AM Wojtas","year":"2024","unstructured":"Wojtas, A. M. et al. Proteomic changes in the human cerebrovasculature in Alzheimer\u2019s disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid. Alzheimers Dement. 20, 4043\u20134065 (2024).","journal-title":"Alzheimers Dement."},{"key":"1123_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2288-4","volume":"11","author":"CS Durrant","year":"2020","unstructured":"Durrant, C. S., Ruscher, K., Sheppard, O., Coleman, M. P. & \u00d6zen, I. Beta secretase 1-dependent amyloid precursor protein processing promotes excessive vascular sprouting through NOTCH3 signalling. Cell Death Dis. 11, 98 (2020).","journal-title":"Cell Death Dis."},{"key":"1123_CR39","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.3390\/ijms24087046","volume":"24","author":"A Badimon","year":"2023","unstructured":"Badimon, A., Torrente, D. & Norris, E. H. Vascular dysfunction in Alzheimer\u2019s disease: alterations in the plasma contact and fibrinolytic systems. Int. J. Mol. Sci. 24, 7046 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1123_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-03003-5","volume":"21","author":"M Shi","year":"2024","unstructured":"Shi, M., Chu, F., Zhu, F. & Zhu, J. Peripheral blood amyloid-\u03b2 involved in the pathogenesis of Alzheimer\u2019s disease via impacting on peripheral innate immune cells. J. Neuroinflammation 21, 5 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1123_CR41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-020-00195-1","volume":"9","author":"Y Cheng","year":"2020","unstructured":"Cheng, Y., Tian, D.-Y. & Wang, Y.-J. Peripheral clearance of brain-derived A\u03b2 in Alzheimer\u2019s disease: pathophysiology and therapeutic perspectives. Transl. Neurodegener. 9, 16 (2020).","journal-title":"Transl. Neurodegener."},{"key":"1123_CR42","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y., Chen, H., Li, R., Sterling, K. & Song, W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct. Target. Ther. 8, 248 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1123_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-020-00413-4","volume":"15","author":"Z Li","year":"2020","unstructured":"Li, Z., Shue, F., Zhao, N., Shinohara, M. & Bu, G. APOE2: protective mechanism and therapeutic implications for Alzheimer\u2019s disease. Mol. Neurodegener. 15, 63 (2020).","journal-title":"Mol. Neurodegener."},{"key":"1123_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.conb.2014.02.012","volume":"27","author":"CG Geoffroy","year":"2014","unstructured":"Geoffroy, C. G. & Zheng, B. Myelin-associated inhibitors in axonal growth after CNS injury. Curr. Opin. Neurobiol. 27, 31\u201338 (2014).","journal-title":"Curr. Opin. Neurobiol."},{"key":"1123_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00921-1","author":"MR Duggan","year":"2026","unstructured":"Duggan, M. R. et al. OMG! A proteomic determinant of neurodegenerative resiliency. Mol. Neurodegener. https:\/\/doi.org\/10.1186\/s13024-025-00921-1 (2026).","journal-title":"Mol. Neurodegener."},{"key":"1123_CR46","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41593-024-01737-w","volume":"27","author":"A Pichet Binette","year":"2024","unstructured":"Pichet Binette, A. et al. Proteomic changes in Alzheimer\u2019s disease associated with progressive A\u03b2 plaque and tau tangle pathologies. Nat. Neurosci. 27, 1880\u20131891 (2024).","journal-title":"Nat. Neurosci."},{"key":"1123_CR47","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00401-024-02819-6","volume":"148","author":"K Balcomb","year":"2024","unstructured":"Balcomb, K. et al. SMOC1 colocalizes with Alzheimer\u2019s disease neuropathology and delays A\u03b2 aggregation. Acta Neuropathol. 148, 72 (2024).","journal-title":"Acta Neuropathol."},{"key":"1123_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41514-023-00112-6","volume":"9","author":"JA Roberts","year":"2023","unstructured":"Roberts, J. A. et al. Unbiased proteomics and multivariable regularized regression techniques identify SMOC1, NOG, APCS, and NTN1 in an Alzheimer\u2019s disease brain proteomic signature. npj Aging 9, 18 (2023).","journal-title":"npj Aging"},{"key":"1123_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/gerona\/glac226","volume":"78","author":"JL S\u00e1nchez-S\u00e1nchez","year":"2023","unstructured":"S\u00e1nchez-S\u00e1nchez, J. L. et al. Periostin plasma levels and changes on physical and cognitive capacities in community-dwelling older adults. J. Gerontol. A 78, 424\u2013432 (2023).","journal-title":"J. Gerontol. A"},{"key":"1123_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12640-018-9922-2","volume":"35","author":"X-L Zhong","year":"2019","unstructured":"Zhong, X.-L. et al. A genome-wide association study of \u03b1-synuclein levels in cerebrospinal fluid. Neurotox. Res. 35, 41\u201348 (2019).","journal-title":"Neurotox. Res."},{"key":"1123_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39013","volume":"10","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Novel targets for the treatment and prevention of Alzheimer\u2019s disease in the European population, inspiration from amyloid beta and tau protein. Heliyon 10, e39013 (2024).","journal-title":"Heliyon"},{"key":"1123_CR52","doi-asserted-by":"publisher","unstructured":"Rooney, M. R. et al. Plasma proteomic comparisons change as coverage expands for SomaLogic and Olink. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2024.07.11.24310161 (2024).","DOI":"10.1101\/2024.07.11.24310161"},{"key":"1123_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm5164","volume":"8","author":"DH Katz","year":"2022","unstructured":"Katz, D. H. et al. Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer- and antibody-based methods. Sci. Adv. 8, eabm5164 (2022).","journal-title":"Sci. Adv."},{"key":"1123_CR54","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn, G. H. et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature 622, 348\u2013358 (2023).","journal-title":"Nature"},{"key":"1123_CR55","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s42004-025-01665-1","volume":"8","author":"DY Kirsher","year":"2025","unstructured":"Kirsher, D. Y. et al. Current landscape of plasma proteomics from technical innovations to biological insights and biomarker discovery. Commun. Chem. 8, 279 (2025).","journal-title":"Commun. Chem."},{"key":"1123_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56935-2","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang, B. et al. Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults. Nat. Commun. 16, 1869 (2025).","journal-title":"Nat. Commun."},{"key":"1123_CR57","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-015-1477-1","volume":"130","author":"Y Xiang","year":"2015","unstructured":"Xiang, Y. et al. Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer\u2019s disease. Acta Neuropathol. 130, 487\u2013499 (2015).","journal-title":"Acta Neuropathol."},{"key":"1123_CR58","doi-asserted-by":"publisher","first-page":"101451","DOI":"10.1016\/j.arr.2021.101451","volume":"71","author":"R Ullah","year":"2021","unstructured":"Ullah, R., Park, T. J., Huang, X. & Kim, M. O. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer\u2019s pathology: insights and therapeutic approaches from periphery. Ageing Res. Rev. 71, 101451 (2021).","journal-title":"Ageing Res. Rev."},{"key":"1123_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-023-00594-8","volume":"18","author":"Z-H Liu","year":"2023","unstructured":"Liu, Z.-H., Wang, Y.-J. & Bu, X.-L. Alzheimer\u2019s disease: targeting the peripheral circulation. Mol. Neurodegener. 18, 3 (2023).","journal-title":"Mol. Neurodegener."},{"key":"1123_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02428-1","volume":"22","author":"X Liu","year":"2024","unstructured":"Liu, X., Shen, L., Wan, M., Xie, H. & Wang, Z. Peripheral extracellular vesicles in neurodegeneration: pathogenic influencers and therapeutic vehicles. J. Nanobiotechnol. 22, 170 (2024).","journal-title":"J. Nanobiotechnol."},{"key":"1123_CR61","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/341226a0","volume":"341","author":"CL Joachim","year":"1989","unstructured":"Joachim, C. L., Mori, H. & Selkoe, D. J. Amyloid beta-protein deposition in tissues other than brain in Alzheimer\u2019s disease. Nature 341, 226\u2013230 (1989).","journal-title":"Nature"},{"key":"1123_CR62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/neurolint17120197","volume":"17","author":"JM Dong","year":"2025","unstructured":"Dong, J. M. & Zhong, H. Systematic review: proteomics-driven multi-omics integration for Alzheimer\u2019s disease pathology and precision medicine. Neurol. Int. 17, 197 (2025).","journal-title":"Neurol. Int."},{"key":"1123_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60185-7","volume":"16","author":"P Ren","year":"2025","unstructured":"Ren, P. et al. Atlas of proteomic signatures of brain structure and its links to brain disorders. Nat. Commun. 16, 5092 (2025).","journal-title":"Nat. Commun."},{"key":"1123_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/21541264.2019.1575159","volume":"10","author":"J-G Zhang","year":"2019","unstructured":"Zhang, J.-G. et al. Identify gene expression pattern change at transcriptional and post-transcriptional levels. Transcription 10, 137\u2013146 (2019).","journal-title":"Transcription"},{"key":"1123_CR65","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/pmic.201300187","volume":"14","author":"B Lollo","year":"2014","unstructured":"Lollo, B., Steele, F. & Gold, L. Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics 14, 638\u2013644 (2014).","journal-title":"Proteomics"},{"key":"1123_CR66","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"1123_CR67","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","volume":"29","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat. Med. 29, 1971\u20131978 (2023).","journal-title":"Nat. Med."},{"key":"1123_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement. 18, 283\u2013293 (2022).","journal-title":"Alzheimers Dement."},{"key":"1123_CR69","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti, C. et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat. Med. 29, 1964\u20131970 (2023).","journal-title":"Nat. Med."},{"key":"1123_CR70","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin. Chem. Lab. Med. 60, 207\u2013219 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"key":"1123_CR71","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470\u20131481 (2018).","journal-title":"Alzheimers Dement."},{"key":"1123_CR72","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2814616\/v1","author":"C Cruchaga","year":"2023","unstructured":"Cruchaga, C. et al. Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and informs causal proteins for Alzheimer\u2019s disease. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-2814616\/v1 (2023).","journal-title":"Res. Sq."},{"key":"1123_CR73","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-024-47971-5","volume":"15","author":"L Karlsson","year":"2024","unstructured":"Karlsson, L. et al. Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases. Nat. Commun. 15, 3676 (2024).","journal-title":"Nat. Commun."},{"key":"1123_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41146-4","volume":"14","author":"E Hartman","year":"2023","unstructured":"Hartman, E. et al. Interpreting biologically informed neural networks for enhanced proteomic biomarker discovery and pathway analysis. Nat. Commun. 14, 5359 (2023).","journal-title":"Nat. Commun."},{"key":"1123_CR75","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.cell.2023.08.039","volume":"186","author":"H Mathys","year":"2023","unstructured":"Mathys, H. et al. Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to Alzheimer\u2019s disease pathology. Cell 186, 4365\u20134385.e27 (2023).","journal-title":"Cell"},{"key":"1123_CR76","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41586-021-04369-3","volume":"603","author":"AC Yang","year":"2022","unstructured":"Yang, A. C. et al. A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk. Nature 603, 885\u2013892 (2022).","journal-title":"Nature"},{"key":"1123_CR77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/pro.3307","volume":"27","author":"PJ Thul","year":"2018","unstructured":"Thul, P. J. & Lindskog, C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 27, 233\u2013244 (2018).","journal-title":"Protein Sci."},{"key":"1123_CR78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnins.2016.00016","volume":"10","author":"NG Skene","year":"2016","unstructured":"Skene, N. G. & Grant, S. G. N. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. Front. Neurosci. 10, 16 (2016).","journal-title":"Front. Neurosci."},{"key":"1123_CR79","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495\u2013502 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1123_CR80","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"1123_CR81","unstructured":"Carlson, M. Org.hs.eg.db: Genome Wide Annotation for Human. Bioconductor https:\/\/bioconductor.org\/packages\/release\/data\/annotation\/html\/org.Hs.eg.db.html (2021)."},{"key":"1123_CR82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nmeth.4083","volume":"14","author":"T Li","year":"2017","unstructured":"Li, T. et al. A scored human protein\u2013protein interaction network to catalyze genomic interpretation. Nat. Methods 14, 61\u201364 (2017).","journal-title":"Nat. Methods"},{"key":"1123_CR83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","volume":"489","author":"MJ Hawrylycz","year":"2012","unstructured":"Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391\u2013399 (2012).","journal-title":"Nature"},{"key":"1123_CR84","doi-asserted-by":"publisher","first-page":"e72129","DOI":"10.7554\/eLife.72129","volume":"10","author":"RD Markello","year":"2021","unstructured":"Markello, R. D. et al. Standardizing workflows in imaging transcriptomics with the abagen toolbox. eLife 10, e72129 (2021).","journal-title":"eLife"},{"key":"1123_CR85","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.neuroimage.2019.01.011","volume":"189","author":"A Arnatkeviciute","year":"2019","unstructured":"Arnatkeviciute, A., Fulcher, B. D. & Fornito, A. A practical guide to linking brain-wide gene expression and neuroimaging data. Neuroimage 189, 353\u2013367 (2019).","journal-title":"Neuroimage"},{"key":"1123_CR86","doi-asserted-by":"publisher","first-page":"117038","DOI":"10.1016\/j.neuroimage.2020.117038","volume":"220","author":"JB Burt","year":"2020","unstructured":"Burt, J. B., Helmer, M., Shinn, M., Anticevic, A. & Murray, J. D. Generative modeling of brain maps with spatial autocorrelation. Neuroimage 220, 117038 (2020).","journal-title":"Neuroimage"}],"container-title":["Nature Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01123-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01123-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01123-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:02:37Z","timestamp":1779289357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43587-026-01123-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":86,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1038\/s43587-026-01123-0","relation":{},"ISSN":["2662-8465"],"issn-type":[{"value":"2662-8465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.M.-C. has received speaker\/consultancy fees from Biogen, BioArctic, Eli Lilly, and Owkin and Merck. O.H. is an employee of Lund University and Eli Lilly. S.P. has acquired research support (for the institution) from ki elements\/ADDF and Avid. In the past 3\u2009years, he has received consultancy\/speaker\u2019s fees from Novo Nordisk, BioArctic, Biogen, Esai, Lilly, and Roche. R.O. is currently a full-time employee of Eli Lilly and Company. His contribution to the work presented in this manuscript was performed as an employee of Amsterdam University Medical Centers and Lund University. R.O. has received research funding\/support from the European Research Council, ZonMw, Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO), National Institute of Health, Alzheimer Association, Alzheimer Nederland, Stichting Dioraphte, Cure Alzheimer\u2019s fund, Health Holland, ERA PerMed, Alzheimerfonden, Hjarnfonden, Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics; he has given lectures in symposia sponsored by GE Healthcare, received speaker fees from Springer, and was an advisory board\/steering committee member for Asceneuron, Biogen, Johnson & Johnson, and Bristol Myers Squibb. All the aforementioned has been paid to Amsterdam University Medical Centers and Lund University. B.M. and A.V. are employees of AbbVie. B.S. is an employee of Johnson & Johnson. J.W.V. has received advisory fees from Manifest Technologies within the past 2\u2009years. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}